Detalhe da pesquisa
1.
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Cancer
; 128(21): 3775-3783, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36101004
2.
Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Pediatr Blood Cancer
; 69(9): e29719, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441784
3.
A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Pediatr Blood Cancer
; 68(10): e29117, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028986
4.
Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature.
Pediatr Blood Cancer
; 67(8): e28236, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386124
5.
A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231).
Pediatr Blood Cancer
; 67(9): e28502, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589362
6.
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.
Pediatr Blood Cancer
; 66(7): e27736, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968542
7.
Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
Pediatr Blood Cancer
; 65(5): e26940, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29350464
8.
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pediatr Blood Cancer
; 65(7): e27023, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603591
9.
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
Pediatr Blood Cancer
; 63(8): 1349-56, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092812
10.
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Biol Blood Marrow Transplant
; 21(4): 673-81, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25639769
11.
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Pediatr Blood Cancer
; 62(10): 1739-46, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26153194
12.
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
Lancet Oncol
; 14(10): 999-1008, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23890779
13.
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
N Engl J Med
; 363(14): 1324-34, 2010 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20879881
14.
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Pediatr Blood Cancer
; 60(11): 1801-8, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23813912
15.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Nat Med
; 29(5): 1092-1102, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012551
16.
The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.
Pediatr Blood Cancer
; 58(5): 675-81, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22493777
17.
Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010.
Pediatr Blood Cancer
; 58(6): 905-9, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21990040
18.
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Pediatr Blood Cancer
; 56(2): 191-201, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20830775
19.
A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
Pediatr Blood Cancer
; 57(2): 275-82, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21671363
20.
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
J Clin Oncol
; 39(31): 3506-3514, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34270348